NATURETIN-5

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NATURETIN-5 (NATURETIN-5).

How it works

Thiazide diuretic that inhibits sodium-chloride symporter in distal convoluted tubule, decreasing sodium and water reabsorption and reducing intravascular volume and blood pressure.

What the body does with it

Metabolism	Not extensively metabolized; undergoes minor hepatic metabolism via CYP450 isoenzymes.
Excretion	Primarily renal (70-80% as unchanged drug); the remainder (20-30%) is eliminated via biliary/fecal routes.
Half-life	Terminal elimination half-life is approximately 18-24 hours; clinically, this supports once-daily dosing and requires renal function monitoring.
Protein binding	Saturable binding to erythrocytes; approximately 95% protein-bound, primarily to albumin.
Volume of Distribution	0.8-1.4 L/kg; indicates extensive extravascular distribution and tissue binding.
Bioavailability	Oral: 60-70%; hepatic first-pass metabolism accounts for reduced bioavailability.
Onset of Action	Oral: 1-2 hours; Intravenous: 5-15 minutes.
Duration of Action	12-24 hours; diuretic and antihypertensive effects may persist for up to 24 hours, allowing for once-daily dosing.

Classification & Brands

Dosing & administration

5 mg orally once daily.

Dosage form	TABLET
Renal impairment	GFR 30-50 mL/min: 2.5 mg once daily; GFR <30 mL/min: avoid use.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B/C: contraindicated.
Pediatric use	Not recommended; safety and efficacy not established.
Geriatric use	Initiate at 2.5 mg orally once daily; titrate cautiously.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NATURETIN-5 (NATURETIN-5).

Breastfeeding	Excreted into breast milk; M/P ratio unknown. Avoid breastfeeding due to potential for adverse effects in the infant, including hypotension and electrolyte disturbances.
Teratogenic Risk	FDA Pregnancy Category D. First trimester: risk of congenital malformations, including neural tube defects, cardiovascular anomalies. Second and third trimesters: increased risk of fetal/neonatal adverse effects like oligohydramnios, renal dysfunction, and skull ossification defects.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Anuria","Hypersensitivity to thiazides or sulfonamides","Severe renal impairment (CrCl <30 mL/min)","Severe hepatic impairment"]

Clinical Precautions

Precautions

["Hypokalemia","Hypomagnesemia","Hyponatremia","Hyperuricemia and gout","Hypercalcemia","Dehydration and orthostatic hypotension","Exacerbation of systemic lupus erythematosus","Metabolic alkalosis","Sulfonamide cross-sensitivity"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

NATURETIN-5

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NATURETIN-5 (NATURETIN-5).

How it works

Thiazide diuretic that inhibits sodium-chloride symporter in distal convoluted tubule, decreasing sodium and water reabsorption and reducing intravascular volume and blood pressure.

What the body does with it

Metabolism	Not extensively metabolized; undergoes minor hepatic metabolism via CYP450 isoenzymes.
Excretion	Primarily renal (70-80% as unchanged drug); the remainder (20-30%) is eliminated via biliary/fecal routes.
Half-life	Terminal elimination half-life is approximately 18-24 hours; clinically, this supports once-daily dosing and requires renal function monitoring.
Protein binding	Saturable binding to erythrocytes; approximately 95% protein-bound, primarily to albumin.
Volume of Distribution	0.8-1.4 L/kg; indicates extensive extravascular distribution and tissue binding.
Bioavailability	Oral: 60-70%; hepatic first-pass metabolism accounts for reduced bioavailability.
Onset of Action	Oral: 1-2 hours; Intravenous: 5-15 minutes.
Duration of Action	12-24 hours; diuretic and antihypertensive effects may persist for up to 24 hours, allowing for once-daily dosing.

Classification & Brands

Dosing & administration

5 mg orally once daily.

Dosage form	TABLET
Renal impairment	GFR 30-50 mL/min: 2.5 mg once daily; GFR <30 mL/min: avoid use.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B/C: contraindicated.
Pediatric use	Not recommended; safety and efficacy not established.
Geriatric use	Initiate at 2.5 mg orally once daily; titrate cautiously.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NATURETIN-5 (NATURETIN-5).

Breastfeeding	Excreted into breast milk; M/P ratio unknown. Avoid breastfeeding due to potential for adverse effects in the infant, including hypotension and electrolyte disturbances.
Teratogenic Risk	FDA Pregnancy Category D. First trimester: risk of congenital malformations, including neural tube defects, cardiovascular anomalies. Second and third trimesters: increased risk of fetal/neonatal adverse effects like oligohydramnios, renal dysfunction, and skull ossification defects.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Anuria","Hypersensitivity to thiazides or sulfonamides","Severe renal impairment (CrCl <30 mL/min)","Severe hepatic impairment"]